TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22542789

Group type: EXPERIMENTAL
Intervention: Echovist(®) at body temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sterile saline at body temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Echovist(®) at room temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile saline at room temperature
Number of subjects: 0
Study: 19188547

Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 19-gauge TBNA
Number of subjects: 50
Study: 17468196

Group type: EXPERIMENTAL
Intervention: Testosterone (sustanon 200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16055865

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 167
Study: 12082326

Group type: EXPERIMENTAL
Intervention: Pressure controlled inverse ratio ventilation (PC‐IRV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High PEEP (15 cm H2O) and usual I:E ratio (1:2)
Number of subjects: 0
Study: 10511068

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times a day with meals for 1 year
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo three times a day with meals for 1 year
Number of subjects: 75
Study: 7589043

Group type: EXPERIMENTAL
Intervention: 200 mg.day-1 bezafibrate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 400 mg.day-1 bezafibrate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination therapy (probucol + bezafibrate)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Probucol concentration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CETP mass
Number of subjects: 26
Study: 2179351

Group type: EXPERIMENTAL
Intervention: Education programme including an information booklet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 84263

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg intramuscularly or 1 mg/kg orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no chlorpromazine)
Number of subjects: 11
Study: 30987526

Group type: EXPERIMENTAL
Intervention: Ear protection during water exposure (ear plugs and headbands, n = 130)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No ear protection (n = 114)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Ear protection during water exposure
Number of subjects: 244

Group type: COMPARATOR
Intervention: No ear protection
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 244
Study: 28303842

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (100 mg, three times a day) one day before examination combined with scopolamine butylbromide (20 mg) 10 min before colonoscopy (Group A)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Pinaverium bromide alone on the day of colonoscopy (100 mg, three times a day) (Group B0)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide alone one day before colonoscopy (100 mg, three times a day) (Group B1)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide alone two days before colonoscopy (100 mg, three times a day) (Group B2)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Scopolamine butylbromide alone (20 mg) before colonoscopy (Group C)
Number of subjects: 1000
Study: 25456093

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (Suboxone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continued Methadone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Suboxone
Number of subjects: 80
Study: 25726210

Group type: EXPERIMENTAL
Intervention: Chia flour (35 g/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22995877

Group type: EXPERIMENTAL
Intervention: Early aggressive (EA) strategy (coronary angiography and, when indicated, revascularization within 72 h)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Initially conservative (IC) strategy (angiography and revascularization only for recurrent ischemia)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Early aggressive (EA) strategy
Number of subjects: 313
Study: 19091409

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation at high-risk prethreshold ROP (early treated - ET)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 401
Study: 17304128

Group type: EXPERIMENTAL
Intervention: Curare during anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: No curare during anesthesia (Control)
Number of subjects: 20
Study: 15310350

Group type: EXPERIMENTAL
Intervention: Oral celecoxib 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12406587

Group type: EXPERIMENTAL
Intervention: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 11 g elderberry concentrate (containing 1.9 g of anthocyanins) diluted with 30 g sucrose
Number of subjects: 16
Study: 9832096

Group type: EXPERIMENTAL
Intervention: Low-dose isoproterenol (3- and 5-microg/min)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.4 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (after drug-free state)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: High-dose isoproterenol infusion and nitroglycerin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 7661125

Group type: EXPERIMENTAL
Intervention: High meat diet (HM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low meat diet (LM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low meat with mineral supplements diet (LS)
Number of subjects: 14
Study: 2788004

Group type: EXPERIMENTAL
Intervention: Enteric coated sodium salicylate 4.8 g daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Enteric coated aspirin 4.8 g daily
Number of subjects: 18
Study: 388397

Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg, increased to 500 mg if warranted)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg, increased to 100 mg if warranted)
Number of subjects: 66
Study: 31488049

Group type: EXPERIMENTAL
Intervention: SamPler, a semi-automated method for gene functional annotation
Number of subjects: 0
Study: 28915304

Group type: EXPERIMENTAL
Intervention: HPV vaccine initiation in 2010
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV vaccine initiation in 2008
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV vaccine initiation in 2009
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV vaccine completion in 2010
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV vaccine completion in 2008
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV vaccine completion in 2009
Number of subjects: 0
Study: 26294061

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 0.2 mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 0.5 mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2 mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Test-retest reliability for 0.5 mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall response to tDCS
Number of subjects: 29
Study: 23379490

Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol once weekly
Number of subjects: 29
Study: 16954519

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 147
Study: 15458450

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg and 80 mg daily)
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study: 10657833

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide therapy (IVCY) for 36 months
Number of subjects: 16
Study: 8841155

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken simultaneously with triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 3 hours before triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 12 hours before triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg taken 24 hours before triazolam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Triazolam without itraconazole
Number of subjects: 10
Study: 1360474

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 6099589

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACTH 4-9 analog
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31434161

Group type: EXPERIMENTAL
Intervention: Barcode-assisted medication administration (BCMA) system
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no BCMA system)
Number of subjects: 4
Study: 29798256

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride Buccal Tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 26362487

Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 171

Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 171
Study: 23886754

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no GH treatment initially)
Number of subjects: 22
Study: 21276660

Group type: EXPERIMENTAL
Intervention: Early excision and grafting (E&G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed skin grafting
Number of subjects: 40
Study: 19601507

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16412989

Group type: EXPERIMENTAL
Intervention: Vitamin therapy (oral folic acid, B‐12, and pyridoxine) for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 42
Study: 12633007

Group type: EXPERIMENTAL
Intervention: General mailing of guidelines to clinicians
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Mailing guidelines targeted to a patient starting treatment
Number of subjects: 443

Group type: COMPARATOR
Intervention: No mailing of guidelines
Number of subjects: 443
Study: 10695290

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (administered once or twice depending on prior vaccination status)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 270
Study: 8936398

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1585759

Group type: EXPERIMENTAL
Intervention: Amitase (0.1%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Micanol (0.1%)
Number of subjects: 72
Study: 4091071

Group type: EXPERIMENTAL
Intervention: Nutritional self‐management program
Number of subjects: 11

Group type: COMPARATOR
Intervention: Caloric restriction without nutritional self‐management program
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Self-control of caloric intake (fruit and vegetable)
Number of subjects: 11
Study: 31178259

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (oral tablets), administered 12 and 2 hours preoperatively, and on the 2nd, 3rd, 4th, and 5th postoperative days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (oral tablets)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28986166

Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg/day for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25862770

Group type: EXPERIMENTAL
Intervention: Ultrasonophoresis with standard treatment (supervised exercises and cryotherapy)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Iontophoresis with standard treatment (supervised exercises and cryotherapy)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard treatment (supervised exercises and cryotherapy) with placebo iontophoresis and placebo ultrasonophoresis
Number of subjects: 88
Study: 24672019

Group type: EXPERIMENTAL
Intervention: High craving trials
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low craving trials
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Behavioral task
Number of subjects: 22
Study: 22207250

Group type: EXPERIMENTAL
Intervention: Music therapy (experimental group listening to recorded music)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 62
Study: 20206790

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg BID with food for 7 days and a morning dose on day 8
Number of subjects: 16
Study: 17827960

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing once a day at school with 1,000 ppm fluoride toothpaste and a home support package encouraging twice-daily toothbrushing
Number of subjects: 428

Group type: COMPARATOR
Intervention: Non-intervention group (no brushing at school or home support package)
Number of subjects: 428
Study: 15910950

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study: 12452235

Group type: EXPERIMENTAL
Intervention: 2.5 mg epidural morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 mg epidural morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 90
Study: 10510952

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg t.d.s.)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.d.)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 8543942

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1688013

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study: 6758825

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily for 2 weeks)
Number of subjects: 5
Study: 30573006

Group type: EXPERIMENTAL
Intervention: Training at home using a mobile box trainer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard training without home access
Number of subjects: 36
Study: 28328847

Group type: EXPERIMENTAL
Intervention: Topical 0.15% isopropyl unoprostone (IU) used 3 times a day for 54 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 26416412

Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients with acute pneumonia (OD-APN)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients with prior pneumonia (OD-PNP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients without pneumonia (OD)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Older controls without OD (H)
Number of subjects: 47
Study: 23317926

Group type: EXPERIMENTAL
Intervention: Whey protein drink (20 g whey protein, 20 g carbohydrates)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Milk protein drink (20 g milk protein, 20 g carbohydrates)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (40 g carbohydrates)
Number of subjects: 237
Study: 21501517

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 22 mcg (low dose, LD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 44 mcg (high dose, HD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: NAb-positive patients
Number of subjects: 101
Study: 19524253

Group type: EXPERIMENTAL
Intervention: Mental verbs with strong nonfactive semantics (e.g., /ji5‐wai4/ 'falsely think')
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control for nonverbal intelligence and general language ability
Number of subjects: 100
Study: 17766523

Group type: EXPERIMENTAL
Intervention: Hudson prong bubble continuous positive airway pressure therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Headbox oxygen treatment (standard care)
Number of subjects: 300
Study: 15128179

Group type: EXPERIMENTAL
Intervention: Night work (23:00 to 07:00)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Day shift and night shift
Number of subjects: 9
Study: 12930116

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (2 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (10.5 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (50 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All three drugs
Number of subjects: 45
Study: 9022603

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of recombinant FSH (Puregon)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Subcutaneous injection of recombinant FSH (Puregon)
Number of subjects: 218
Study: 7943099

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2906019

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 30171823

Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Joint replacement, past use of steroids, acid reflux/GERD
Number of subjects: 2163
Study: 28635218

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined treatment of 3.0% saline nasal irrigation and budesonide nasal spray
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with 3.0% saline
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 101
Study: 26232815

Group type: COMPARATOR
Intervention: Conventional therapy (topical sodium chloride, timolol, and betamethasone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Systemic normobaric oxygen at a flow rate of 10 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transcorneal oxygen at a flow rate of 5 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Number of subjects: 45
Study: 23927913

Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 or 5 mg daily for 1 year)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (for 1 year)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Risedronate (during years 2 and 3)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (during years 2 and 3)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 21926632

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 21 days (period 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg once daily for 14 days (period 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800 mg once daily (period 3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily (group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raltegravir alone
Number of subjects: 24
Study: 18310192

Group type: EXPERIMENTAL
Intervention: StudentBodies2‐BED (n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Wait-list control group (n = 53)
Number of subjects: 105
Study: 16754287

Group type: EXPERIMENTAL
Intervention: Awareness Intervention Programme (AIP) for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional rehabilitation programme for 4 weeks
Number of subjects: 21
Study: 12842506

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 60

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 60
Study: 10910659

Group type: EXPERIMENTAL
Intervention: Obese pupils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal body weight pupils)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (obese and non-obese pupils)
Number of subjects: 0
Study: 8891011

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine at 3 mg/kg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Topical 0.05% beta‐methasone‐17,21‐dipropionate (BDP) cream
Number of subjects: 41
Study: 1898717

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d (increased to 40 mg/d for some patients)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 96
Study: 6601256

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sulfisoxazole and placebo
Number of subjects: 35
Study: 3157939

Group type: EXPERIMENTAL
Intervention: Polyethylene catheters used in group A for a mean period of 9 +/- 1 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Teflon catheters used in group B for a mean period of 11 +/- 1 days
Number of subjects: 84
Study: 28895787

Group type: EXPERIMENTAL
Intervention: Internet-based Acceptance and Commitment Therapy (8 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 61
Study: 27364407

Group type: EXPERIMENTAL
Intervention: Spinning physical training program (group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: General gymnastics program (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet alone (group A)
Number of subjects: 30
Study: 24947578

Group type: EXPERIMENTAL
Intervention: Cognitive pc-training in addition to conventional treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35